Literature DB >> 17020951

Kaposi's sarcoma-associated herpesvirus ori-Lyt-dependent DNA replication: dual role of replication and transcription activator.

Yan Wang1, Qiyi Tang, Gerd G Maul, Yan Yuan.   

Abstract

Lytic replication of Kaposi's sarcoma-associated herpesvirus (KSHV) is essential for viral propagation and pathogenicity. In Kaposi's sarcoma lesions, constant lytic replication plays a role in sustaining the population of latently infected cells that otherwise are quickly lost by segregation of latent viral episomes as spindle cells divide. Lytic DNA replication initiates from an origin (ori-Lyt) and requires trans-acting elements. Two functional ori-Lyts have been identified in the KSHV genome. Some cis-acting and trans-acting elements for ori-Lyt-dependent DNA replication have been found. Among these, K8 binding sites, a cluster of C/EBP binding motifs, and a replication and transcription activator (RTA) responsive element (RRE) are crucial cis-acting elements. Binding of K8 and RTA proteins to these motifs in ori-Lyt DNA was demonstrated to be absolutely essential for DNA replication. In the present study, functional roles of RTA in ori-Lyt-dependent DNA replication have been investigated. Two distinct functions of RTA were revealed. First, RTA activates an ori-Lyt promoter and initiates transcription across GC-rich tandem repeats. This RTA-mediated transcription is indispensable for DNA replication. Second, RTA is a component of the replication compartment, where RTA interacts with prereplication complexes composed of at least six core machinery proteins and K8. The prereplication complexes are recruited to ori-Lyt DNA through RTA, which interacts with the RRE, as well as K8, which binds to a cluster of C/EBP binding motifs with the aid of C/EBP alpha. The revelation of these two functions of RTA, together with its role in initiation of a transcriptional cascade that leads to transcription of all viral lytic genes, shows that RTA is a critical initiator and regulator of KSHV lytic DNA replication and viral propagation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020951      PMCID: PMC1676287          DOI: 10.1128/JVI.00990-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication.

Authors:  Alexander C Garber; Jianhong Hu; Rolf Renne
Journal:  J Biol Chem       Date:  2002-05-15       Impact factor: 5.157

2.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA.

Authors:  M E Ballestas; K M Kaye
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Functional characterization of Kaposi's sarcoma-associated herpesvirus ORF45 by bacterial artificial chromosome-based mutagenesis.

Authors:  Fan Xiu Zhu; Xiaojuan Li; Fuchun Zhou; Shou-Jiang Gao; Yan Yuan
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

4.  Annexation of the interchromosomal space during viral infection.

Authors:  K Monier; J C Armas; S Etteldorf; P Ghazal; K F Sullivan
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

5.  Interaction with the Epstein-Barr virus helicase targets Zta to DNA replication compartments.

Authors:  G Liao; F Y Wu; S D Hayward
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus lytic origin (ori-Lyt)-dependent DNA replication: identification of the ori-Lyt and association of K8 bZip protein with the origin.

Authors:  Cui Li Lin; Hong Li; Yan Wang; Fan Xiu Zhu; Sagar Kudchodkar; Yan Yuan
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Principal role of TRAP/mediator and SWI/SNF complexes in Kaposi's sarcoma-associated herpesvirus RTA-mediated lytic reactivation.

Authors:  Yousang Gwack; Hwa Jin Baek; Hiroyuki Nakamura; Sun Hwa Lee; Michael Meisterernst; Robert G Roeder; Jae U Jung
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

8.  Cell cycle arrest by Kaposi's sarcoma-associated herpesvirus replication-associated protein is mediated at both the transcriptional and posttranslational levels by binding to CCAAT/enhancer-binding protein alpha and p21(CIP-1).

Authors:  Frederick Y Wu; Shizhen Emily Wang; Qi-Qun Tang; Masahiro Fujimuro; Chuang-Jiun Chiou; Qizhi Zheng; Honglin Chen; S Diane Hayward; M Daniel Lane; Gary S Hayward
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains two functional lytic origins of DNA replication.

Authors:  David P AuCoin; Kelly S Colletti; Yiyang Xu; Sylvia A Cei; Gregory S Pari
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression.

Authors:  Yoshihiro Izumiya; Su-Fang Lin; Thomas Ellison; Ling-Yu Chen; Chie Izumiya; Paul Luciw; Hsing-Jien Kung
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  51 in total

1.  Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

2.  Interaction of Kaposi's sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on binding with K-Rta.

Authors:  Cyprian C Rossetto; Ni Ketut Susilarini; Gregory S Pari
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  Overexpression of the kaposi's sarcoma-associated herpesvirus transactivator K-Rta can complement a K-bZIP deletion BACmid and yields an enhanced growth phenotype.

Authors:  Taeko Kato-Noah; Yiyang Xu; Cyprian C Rossetto; Kelly Colletti; Iva Papousková; Gregory S Pari
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

4.  Promoter- and cell-specific transcriptional transactivation by the Kaposi's sarcoma-associated herpesvirus ORF57/Mta protein.

Authors:  Diana Palmeri; Sophia Spadavecchia; Kyla Driscoll Carroll; David M Lukac
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

5.  Transcriptional repression of K-Rta by Kaposi's sarcoma-associated herpesvirus K-bZIP is not required for oriLyt-dependent DNA replication.

Authors:  Cyprian Rossetto; Yang Gao; Irena Yamboliev; Iva Papousková; Gregory Pari
Journal:  Virology       Date:  2007-09-21       Impact factor: 3.616

6.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.

Authors:  Wei Bu; Kyla Driscoll Carroll; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

7.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

8.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.

Authors:  Zhiqiang Qin; Patricia Kearney; Karlie Plaisance; Chris H Parsons
Journal:  J Leukoc Biol       Date:  2010-01       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.